Skip to main content Accessibility help
  • Print publication year: 2013
  • Online publication date: April 2011

Chapter 53 - Antimotility and antisecretory drugs


1. Tack J. Receptors of the enteric nervous system: potential targets for drug therapy. Gut 2000; 47: 20–2.
2. Wallmark B, Lorentzon P, Sachs G. The gastric H+, K+-ATPase. J Intern Med 1990; 228: 3–8.
3. Monaghan T, Boswell T, Mahida YR. Recent advances in Clostridium difficile-associated disease. Gut 2008; 57: 850–60.
4. Feldman M, Burton ME. Histamine2-receptor antagonists. Standard therapy for acid-peptic diseases. N Eng J Med 1990; 323: 1672–80.
5. Cantu TG, Korek JS. Central nervous system reactions to histamine-2 receptor blockers. Ann Intern Med 1991; 114: 1027–34.
6. Somogyi A, Gugler R. Clinical pharmacokinetics of cimetidine. Clin Pharmacokinet 1983; 8: 463–95.
7. Hughes DG, Dowling EA, DeMeersman RE, Garnett WR, Karnes HT. Cardiovascular effects of H2-receptor antagonists. J Clin Pharmacol 1989; 29: 472–7.
8. McGuigan JE. A consideration of the adverse effects of cimetidine. Gastroenterology 1981; 80: 181–92.
9. Hernandez-Monoz R, Cabacleria J, Baraona E, et al. Human gastric alcohol dehydrogenase: its inhibition by H2-receptor antagonists, and its effect on the bioavailability of ethanol. Alcoholism 1990; 14: 946–50.
10. Steinberg WM, Lewis JH, Katz DM. Antacids inhibit absorption of cimetidine. N Eng J Med 1982; 307: 400–4.
11. Damman HG, Muller P, Simon B. 24 hour intragastric acidity and single night-time dose of three H2 blockers. Lancet 1983; 2: 1078.
12. Spencer CM, Foulds D. Esomeprazole. Drugs 2000; 60; 321–9.
13. Lorentzon P, Jackson R, Wallmark B, Sachs G. Inhibition of H K-ATPase by omeprazole in isolated gastric vesicles requires proton transport. Biochem Biophys Acta 1987; 897: 41–51.
14. Larsson H, Carlsson E, Junggren U, et al. Animal studies with omeprazole, a potent inhibitor of gastric acid secretion. Scand J Gastroenterol 1982; 17 (Suppl): 76.
15. Carlsson E, Larsson H, Mattsson H, Ryberg B, Sundell G. Pharmocology and toxicology of omeprazole-with special reference to the effects on the gastric mucosa. Scand J Gastroenterol 1986; 118: 31–8.
16. Howden CW, Forrest JA, Reid JL. Effects of single and repeated doses of omeprazole on gastric and pepsin secretion in man. Gut 1984; 25: 707–10.
17. Sachs G. Proton pump inhibitors and acid related diseases. Pharmacotherapy 1997; 17: 22–37.
18. Richardson P, Hawkey CJ, Stack WA. Proton pump inhibitors: pharmacology and rationale for use in gastrointestinal disorders. Drugs 1998; 56; 307–35.
19. Petite JP, Salducci J, Grimaud JC, et al. Lansoprazole versus omeprazole in the treatment of reflux oesophagitis. Med Chir Dig 1995; 24: 291–4.
20. Corinaldesi R, Valentini M, Belaiche J, et al. Pantoprazole and omeprazole in the treatment of reflux oesophagitis: a European multicentre study. Aliment Pharmacol Ther 1995; 9: 667–71.
21. Thjodleifsson B, Beker JA, Dekkers C, et al. Rabeprazole versus omeprazole in preventing relapse of erosive or ulcerative gastroesophageal reflux disease. Dig Dis Sci 2000; 45: 845–53.
22. Marshall BJ, Warren JR. Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. Lancet 1984; 1: 1311–15.
23. Collins R, Langman M. Treatment with histamine H2 antagonists in acute upper gastrointestinal hemorrhage: implications of randomised trials. N Eng J Med 1985; 313: 660–6.
24. Leontiadis GI, Sreedharan A, Dorward S, et al. Systematic reviews of the clinical effectiveness and cost-effectiveness of proton pump inhibitors in acute upper gastrointestinal bleeding. Health Technol Assess 2007; 11: 1–164.
25. Hawkey CJ, Karrasch JA, Szczepanski L, et al. Omeprazole compared to misoprostol for ulcers associated with nonsteroidal antiinflammatoro drugs. N Eng J Med 1998; 338: 727–34.
26. Yeomans ND, Tulassay Z, Juhasz L, et al. A comparison of omeprazole with ranitidine for ulcers associated with nonsteroidal anti-inflammatory drugs. N Eng J Med 1998; 338: 719–26.
27. Cook DJ, Reeve BK, Guyatt GH, et al. Stress ulcer prophylaxis in critically ill patients: resolving discordant meta-analysis. JAMA 1996: 275: 308–14.
28. Ewart MC, Yau G, Gin T, Kotur CF, Oh TE. A comparison of the effects of omeprazole and ranitidine on gastric secretion in women undergoing elective caesarian section. Anesthesiology 1990; 45: 527–30.
29. Ruskone A, Rene E, Chayvialle JA, et al. Effect of somatostatin on diarrhoea and on small intestinal water and electrolyte transport in a patient with pancreatic cholera. Dig Dis Sci 1982: 27: 459–66.
30. Efendic S, Mattson O. Effect of somatostatin on intestinal motility. Acta Radiol Diag 1978: 19: 348–52.
31. Bloom SR. Somatostatin and the gut. Gastroenterology 1978: 75: 145–7.
32. Viollet C, Prevost G, Maubert E, et al. Molecular pharmacology of somatostatin receptors. Fundam Clin Pharmacol 1995; 92: 107–113.
33. Gyr KE, Meier R. Pharmacodynamic effects of sandostatin in the gastrointestinal tract. Digestion 1993; 54: 14–19.
34. Harris AG. Somatostatin and somatostatin analogues: pharmacokinetics and pharmacodynamic effects. Gut 1994; 35: S1–4.
35. Bornschein J, Drozdov I, Malfertheiner P. Octreotide LAR: safety and tolerability issues. Expert Opin Drug Saf 2009; 8: 755–68.
36. O'Keefe SJ, Peterson ME, Fleming CR. Octreotide as an adjunct to home parenteral nutrition in the management of permanent end-jejunostomy syndrome. J Parenter Enteral Nutr 1994; 18: 26–34.
37. Seydel AS, Miller JH, Sarac TP, et al. Octreotide diminishes luminal nutrient transport activity, which is reversed by epidermal growth factor. Am J Surg 1996; 172: 267–71.
38. O'Keefe SJD, Haymond MW, Bennet WM, et al. Long-acting somatostatin analogue therapy and protein metabolism in patients with jejunostomies. Gastroenterology 1994; 107: 379–88.
39. Cotton PB. Progress report. ERCP. Gut 1977; 18: 316–41.
40. McGrath WR, Lewis RE, Kuhn WL. The dual mode of the antispasmodic efffct of dicyclomine hydrochloride. J Pharmacol Exp Ther 1964; 146: 354–8.
41. Maxton DG, Morris J, Whorwell PJ. Selective 5-hydroxytryptamine antagonism: a role in irritable bowel syndrome and functional dyspepsia? Aliment Pharmacol Ther 1996; 10: 595–9.
42. Prior A, Read NW. Reduction of rectal sensitivity and post-prandial motility by granisetron, a 5-HT3 receptor antagonist, in patients with irritable bowel syndrome. Aliment Pharmacol Ther 1993: 7: 175–80.
43. Goldberg PA, Kamm MA, Setti-Carraro P, van der Sijp JR, Roth C. Modification of visceral sensitivity and pain and irritable bowel syndrome by 5-HT3 antagonism (ondansetron). Digestion 1996: 57: 478–83.
44. Kozlowski CM, Green A, Grundy D, Boissonade FM, Bountra C. The 5-HT3 receptor antagonist alosetron inhibits the colorectal induced depressor response and spinal c-fos expression in the anaesthetised rat. Gut 2000; 46: 474–80.
45. Balfour JA, Goa KL, Perry CM. Alosetron (review). Drugs 2000; 59; 511–18.
46. Miura M, Lawson DC, Clary DM, Mangel AW, Pappas TN. Central modulation of rectal distension-induced blood pressure changes by alosetron, a 5HT3 receptor antagonist. Dig Dis Sci 1999; 44: 20–4.
47. Camilleri M, Mayer E, Drossman D, et al. Improvement in pain with alosetron, a 5-HT3-receptor antagonist. Aliment Pharmacol Ther 1999; 14: 1149–51.
48. Camilleri M, Northcutt AR, Kong GE, McSorley D, Mangel AW. Efficacy and safety of alosetron in women with irritable bowel syndrome: a randomised, placebo-controlled trial. Lancet 2000; 355: 1035–40.
49. Friedel D, Thomas R, Fisher RS. Ischaemic colitis during treatment with Alosetron. Gastroenterology 2001; 120: 557–60.
50. Coupar IM. Opioid action on the intestine: the importance of the intestinal mucosa. Life Sci 1987; 41: 917–25.
51. Jaffe JH, Martin WR. Opioid analgesics and antagonists. In: Gilman AG, Goodman LS, Rall TW, Murad F, eds., The Pharmacological Basis of Therapeutics, 7th edn. New York, NY: Macmillan, 1985: 491–531.
52. Burleigh DE. Loperamide but not morphine has anti-secretory effects in human colon in vitro. Eur J Pharmacol 1991: 202: 277–280.
53. Read M, Read NW, Barber DC, Duthie HL. Effects of loperamide on anal sphincter function in patients complaining of chronic diarrhoea with faecal incontinence and urgency. Dig Dis Sci 1982: 27: 807–14.
54. Forbes A. Clinicians' Guide to Inflammatory Bowel Disease. London: Chapman & Hall, 1997.
55. Brown JW. Toxic megacolon associated with loperamide therapy. J Am Med Assoc 1979: 241: 501–2.
56. Palmer KR, Corbett CL, Holdsworth CD. Double-blind crossover study comparing loperamide, codeine and diphenoxylate in the treatment of chronic diarrhoea. Gastroenterology 1980; 79: 1272–5.
57. Pelemans W, Vantrappen G. A double blind crossover comparison of loperamide with diphehoxylate in the symptomatic treatment of chronic diarrhoea. Gastroenterology 1976; 70: 1030–4.
58. Schulz H. Clinical use of E. coli Nissle 1917 in inflammatory bowel disease. Inflamm Bowel Dis 2008; 14: 1012–18.
59. O'Mahony L, McCarthy J, Kelly P, et al. Lactobacillus and bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles. Gastroenterology 2005; 128: 541–51.
60. McFarland LV, Surawicz CM, Greenberg RN, et al. A randomised placebo-controlled trial of Saccharomyces boulardii in combination with standard antibiotics for Clostridium difficile disease. JAMA 1994; 271: 1913–18.
61. Cherifi S, Robberecht J, Miendje Y. Saccharomyces cerevisiae fungemia in an elderly patient with Clostridium difficile colitis. Acta Clin Bel 2004; 59: 223–4.
62. Sanger GJ, Alpers DH. Development of drugs for gastrointestinal motor disorders: translating science to clinical need. Neurogastroenterol Motil 2008; 20: 177–84.